Bryant Furlow

Lorlatinib exhibits durable responses in patients with ALK-positive non–small-cell lung cancer and robust intracranial activity in those with brain metastases.

Adding daratumumab to standard of care is a feasible alternative to autologous stem cell transplantation with standard regimens in multiple myeloma patients.

Atezolizumab treatment beyond progression might benefit patients with advanced non–small-cell lung cancer, according to the first report from the randomized phase III OAK trial.

Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy, according to analyses of two phase III clinical trials.

A molecular signature for aggressive-variant prostate carcinoma can predict which men with castration-resistant prostate cancer will benefit from cabazitaxel with or without carboplatin.

Researchers are making much-needed progress in developing treatments for patients with three rare malignancies: recurrent and refractory primary central nervous (CNS) system lymphoma, secondary CNS lymphoma, and primary vitreoretinal lymphoma.

Liver toxicity precludes development of pembrolizumab plus pazopanib immunotherapy for patients with advanced renal cell carcinoma.

Despite previously reported progression-free survival improvements with cediranib, results from the ICON6 trial failed to show a statistically significant improvement in overall survival.

The investigational third-generation nonsteroidal oral selective estrogen receptor degrader RAD1901 was associated with a 23% objective response rate among 40 heavily pretreated women with estrogen receptor (ER)-positive, HER2-negative breast cancer.

Adding ipatasertib to first-line paclitaxel modestly improved progression-free survival in women with triple-negative breast cancer.

Plasma levels of HGF, BAP1 and PBRM1 gene mutation status, and angiogenesis gene expression are promising predictive biomarkers for survival in RCC patients.

Despite high rates of toxicity, a first-line tyrosine kinase inhibitor/immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma.

Adjuvant radiotherapy for diffuse large B-cell lymphoma is unnecessary for elderly patients who have PET-negative bulky disease following immunochemotherapy.

Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma.

Prognostic somatic copy number alterations in diffuse large B-cell lymphoma can be detected and monitored noninvasively using ctDNA from patient plasma.

Abemaciclib plus fulvestrant was linked with improved response and PFS in patients with endocrine-resistant, HR-positive, HER2-negative metastatic breast cancer.

Palbociclib alone and in combination with endocrine therapy offers clinical benefit among women with HR-positive, HER2-negative metastatic breast cancer.

Adding bevacizumab to neoadjuvant chemotherapy did not improve complete macroscopic response rate or progression-free survival in women with ovarian cancer.

Platinum-sensitive ovarian cancer patients with a positive predictive AGO score who undergo a secondary debulking surgery after relapse on platinum chemotherapy experience longer progression-free survival.

Despite toxicity, olaparib maintenance therapy is associated with improved patient-reported symptoms outcomes and improved quality-adjusted progression-free survival among patients with germline BRCA mutation-positive, platinum-sensitive relapsed serious ovarian cancer.

It is increasingly important that nurses recognize cytokine release syndrome and other side effects that can be triggered by treatment with engineered CAR T-cell therapies.

Women undergoing robotic surgery procedures for gynecologic cancers and nonmalignant conditions report more patient education needs than those undergoing traditional laparotomy.

Oncology nurses must navigate an increasingly complex web of state medical marijuana laws, with varying provisions and roles for healthcare providers.

Oncology nurses and others should pay close attention to their patients’ quality-of-life concerns, but what that means will vary from patient to patient.

Chlorhexidine wipe bathing might help reduce the risk of deadly central line-associated bloodstream infections (CLABSIs) among cancer inpatients, but barriers can complicate implementation efforts.

Gum chewing might help patients avoid prolonged intestinal motility dysfunction following abdominal cancer surgery, suggested findings reported at the ONS Congress.

Improving oropharyngeal cancer survival rates necessitates better coordination of survivorship care between oncology teams and primary care providers, according to a presentation at ONS.

Nurse practitioners play a central role in helping patients with esophageal cancer understand and manage their disease and treatment complications.

Electronic medical record and telephone triage systems should be updated to reflect the unique risks of immune-related side effects faced by patients undergoing cancer immunotherapies.

Patient education can improve adherence to skin-care plans and reduce radiation dermatitis among patients undergoing radiotherapy for breast cancer.